• <code id="kgams"><tr id="kgams"></tr></code>
      <abbr id="kgams"></abbr>
    • <abbr id="kgams"></abbr>
      Home
      Who We Are
      What We Do
      Corporate Responsibility
      News
      Careers
      Investors
      Patients and HCPS
      Contact us
      Careers | Investors | Patients and HCPS | Contact us
      Home / Company News / Gan & Lee Pharmaceuticals Begins First-In-Human Trial in the U.S. for Investigational Drug, GZR18
      Gan & Lee Pharmaceuticals Begins First-In-Human Trial in the U.S. for Investigational Drug, GZR18
      Date:2022-03-10

      Beijing, China/Bridgewater, New Jersey U.S, March 10, 2022 — Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled, sequential, single, ascending dose clinical study in the U.S. for the company’s investigational drug, GZR18.

       

      GZR18 is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with the potential to treat patients with type 2 diabetes. Currently, type 2 diabetes mellitus accounts for approximately 90% of all diabetes cases while a 46% increase in the number of people with diabetes is expected by 2045, globally1 。Glucagon-like peptide-1 (GLP-1) is an incretin hormone responsible for many glucoregulatory effects such as the stimulation of insulin secretion and the inhibition of glucagon when blood glucose is high2. Many of these glucoregulatory effects are often impaired in patients with type 2 diabetes3.

       

      The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers. In addition, the secondary objective is to determine the pharmacokinetic (PK) parameters of GZR18. “The start of this Phase 1 clinical trial of GZR18 at a U.S. site, is a significant milestone for our global clinical development program. This trial demonstrates Gan & Lee’s long-term commitment to strengthening our pipeline in diabetes and other therapeutic areas to benefit the patient and medical community” said Dr. Mike Hu, the Chief Executive Officer (CEO) & President of Gan & Lee Pharmaceuticals USA Corporation.



      References

      1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

      2. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr; 46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14. PMID: 33068776; PMCID: PMC8085572. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551568/

      3. Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 2020 Nov;132(sup2):3-14. doi: 10.1080/00325481.2020.1798099. Epub 2020 Sep 8. PMID: 32815454




      About Gan & Lee

      Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

       

      In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 





      Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網(wǎng)安備 11011202003900號
      Our websites

      Subscribe

      • China
        US
        Europe
        Others
      I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
      主站蜘蛛池模板: 国产真实乱子伦精品视手机观看| www..99557c..com| 国产精品永久免费| 性色av一区二区三区| 最近2019免费中文字幕视频三| 亚洲综合丁香婷婷六月香| 99视频免费在线观看| 下载一个黄色录像| 久久久久无码中| 久久亚洲中文字幕无码| 亚洲av成人一区二区三区| 亚洲精品tv久久久久久久久久| 免费看男女下面日出水视频| 国产91中文剧情在线观看| 国产传媒一区二区三区呀| 国产女人高潮视频在线观看| 国产激情精品一区二区三区| 国产欧美日韩综合精品二区| 国产精品无码专区| 国产精品日本亚洲777| 国产成人3p视频免费观看| 无码一区二区三区免费| 亚洲中久无码永久在线观看同| 亚洲最大综合网| 啊灬啊灬啊灬快灬深高潮了| 国产91乱剧情全集| 亚洲精品成人久久| 亚洲国产精品免费在线观看| 亚洲五月综合缴情婷婷| 五十路在线播放| 久久综合久久久久| 久久久精品一区二区三区| 99精品国产成人a∨免费看| 黄瓜视频网站在线观看| 香蕉在线精品一区二区| 韩国免费三片在线视频| 蜜桃臀无码内射一区二区三区| 色狠狠久久av五月综合| 精品福利视频导航| 精品400部自拍视频在线播放| 污网站视频在线观看|